Recently, we received an order from a customer in Russia. The customer purchased AOD 9604 and GHK-CU raw material powder, and specified specific packaging requirements. They requested that the AOD 9604 powder be divided into four portions.
We strictly followed the customer's requirements to carry out the operation. We precisely packaged the AOD 9604 powder to ensure that each package met the standards. After the packaging was completed, we took photos of the packaged products and sent the photos to the customer for their confirmation of the packaging status. Subsequently, we have properly packed the goods and are preparing to send them to the customer's designated address. The entire process aims to ensure the stability and safety of the products during transportation, in order to meet the customer's usage needs.
AOD 9604: Exploration of Synthetic Peptides Targeting Lipid Metabolism
AOD 9604 is a synthetic peptide fragment composed of 30 amino acid residues. Its chemical structure is derived from the C-terminal region of human growth hormone (amino acids 176-191), with tyrosine residues added to enhance stability. As the "lipolytic domain" of growth hormone, AOD 9604 is designed to target and regulate fat metabolism. Its core mechanism lies in activating fat breakdown (lipolysis) and inhibiting fat production, while avoiding the systemic endocrine side effects caused by traditional growth hormone therapy.
Research Background and Mechanism Analysis
In the late 1990s, researchers used gene editing technology to isolate the specific segment in hGH that is responsible for fat metabolism. They discovered that this segment (namely AOD 9604) can function independently of the growth hormone receptor. Animal experiments showed that AOD 9604 enhances the expression of lipolytic receptors in adipose tissue, promoting the breakdown of triglycerides into free fatty acids, while inhibiting the activity of genes related to fat cell differentiation, thereby reducing fat accumulation. Unlike the complete growth hormone, AOD 9604 does not stimulate the secretion of insulin-like growth factor-1 (IGF-1), thus avoiding the metabolic disorder risks such as high blood sugar and insulin resistance that may be caused by long-term use of growth hormone.
Clinical research and safety verification
In the early clinical trials, AOD 9604 demonstrated significant effects in obese rodent models: when administered orally at a dose of 500 micrograms per kilogram for 19 consecutive days, AOD 9604 reduced the weight gain of obese rats by more than 50%, while enhancing the expression of fat oxidation markers. In human trials, after a single oral administration of 1 milligram of AOD 9604, flu symptoms (such as coughing and fever) were relieved within 24 hours, suggesting that it may indirectly affect immune function by regulating metabolic pathways. However, subsequent large-scale Phase IIb clinical trials failed to replicate the weight loss efficacy, leading to the suspension of development. Nevertheless, AOD 9604 is still classified as a prohibited substance by anti-doping agencies, reflecting the controversial nature of its metabolic regulatory potential in the field of sports competitions.
Application fields and future directions
Currently, AOD 9604 is mainly used as a research tool to explore the molecular mechanisms of fat tissue metabolism. For instance, in a rabbit model of knee joint osteoarthritis, intrajoint cavity injection of AOD 9604 combined with hyaluronic acid can significantly promote cartilage regeneration, and its effect is superior to that of single-component treatment. Moreover, the application potential of AOD 9604 in areas such as cartilage repair and metabolic syndrome management is still being explored. Although it has not yet been approved by regulatory agencies for clinical treatment, its targeted design provides important references for the development of new anti-obesity drugs.
GHK-Cu: The Miracle of Repair and Regeneration of Blue Copper Peptide
GHK-Cu (a naturally occurring tripeptide-copper complex, named "blue copper peptide" due to its blue color in aqueous solution) is a copper-bound tripeptide compound. In 1973, biochemist Loren Picard isolated the GHK tripeptide from human plasma for the first time and discovered that it has a high affinity for copper ions and can form a bioactive GHK-Cu complex. This discovery has opened up extensive applications of copper peptides in fields such as medical aesthetics and tissue repair.
Structural characteristics and biological functions
GHK-Cu is formed by the connection of three amino acids - glycine, histidine, and lysine - through peptide bonds. It also forms a stable complex with copper ions (Cu²⁺) through the imidazole ring of the histidine side chain and the nitrogen atom in the peptide bond. This structure endows GHK-Cu with multiple biological functions:
Promote collagen synthesis: GHK-Cu can upregulate the gene expression of collagen, elastin and glycosaminoglycans in fibroblasts, enhancing skin elasticity and thickness.
Antioxidation and Anti-Inflammation: By activating antioxidant enzymes such as superoxide dismutase (SOD), GHK-Cu can eliminate free radicals, inhibit the release of inflammatory factors (such as TNF-α, IL-6), and alleviate skin redness, swelling and sensitivity.
Accelerated wound healing: GHK-Cu can attract immune cells and endothelial cells to migrate towards the wound, promoting angiogenesis and tissue remodeling, shortening the healing time and reducing scar formation.
Hair growth and hair follicle repair: Animal experiments have shown that local application of GHK-Cu can increase the number of hair follicles and promote hair growth, and its effect is comparable to that of minoxidil.
Clinical Application and Technological Innovation
Since 1999, when a certain company launched an anti-aging brand containing GHK-Cu, this ingredient has been widely used in skin care products such as serums and masks. Clinical studies have confirmed that using a cream containing GHK-Cu for 12 consecutive weeks can significantly improve skin laxity, fine lines and pigmentation. Its effect is superior to that of traditional anti-aging ingredients such as vitamin C. To overcome the problems of GHK-Cu being prone to inactivation and poor penetration, researchers have developed technologies such as liposome encapsulation and nano carriers. For example, GHK-Cu liposomes prepared by the reverse evaporation method can increase stability by more than 40%.
Expanding into multiple fields and conducting cutting-edge exploration
The application of GHK-Cu has gone beyond the realm of beauty and has extended to medical treatment and biotechnology fields.
Chronic wound care
The intelligent dressing containing GHK-Cu can accelerate the healing of difficult-to-heal wounds such as diabetic foot ulcers through its antioxidant, anti-inflammatory and antibacterial effects.
Treatment of pulmonary fibrosis
Animal experiments have shown that GHK-Cu can inhibit bleomycin-induced pulmonary fibrosis and reduce the levels of inflammatory factors, providing a potential treatment option for interstitial lung diseases.
New type of biomaterial
The coupling technology of GHK-Cu and 316L medical stainless steel can maintain its metabolic activity in dynamic living scenarios, expanding its application potential in wearable devices.
Conclusion
AOD 9604 and GHK-Cu respectively represent the innovative applications of synthetic peptides and natural peptides in the field of biomedicine. The former explores new paths for anti-obesity through targeting fat metabolism, while the latter becomes a "star ingredient" in beauty and regenerative medicine due to its multi-effect repair mechanism. Although both face challenges in clinical translation, their scientific value and industrial potential continuously push the boundaries of peptide research and development, bringing more possibilities for human health and beauty.
